TG Therapeutics Inc. (NASDAQ: TGTX) has announced the timetable of data presentations showing data from ULTIMATE I & II third phase studies evaluating ublituximab in patients with relapsing multiple sclerosis at the upcoming America Committee for Treatment and Research in Multiple Sclerosis annual forum between February 24 to 26, 2022 in West Palm Beach, Florida.
TG Therapeutics has three presentations accepted at ACTRIMS
Chief Executive Officer and Chairman of TG Therapeutics Michael S. Weiss stated, “We are pleased to have three abstracts accepted for presentation at the upcoming ACTRIMS forum, highlighting additional analyses from the ULTIMATE I & II Phase 3 trials. Each new analysis continues to be encouraging, and we believe reinforces the utility of ublituximab as a potential treatment option for patients with RMS. We look forward to sharing the full data sets at the upcoming ACTRIMS meeting.”
The company will present the first poster title, “Reduction in T1 Hypointense Lesions With Ublituximab vs. Teriflunomide in the Phase 3 ULTIMATE I and II Studies in Relapsing Multiple Sclerosis,” on Thursday, February 24, 2022, by lead author Bruce Cree of UCSF Weill Institute for Neurosciences, University of California San Francisco. The University of Colorado, Aurora’s Enrique Alvarez will also present a poster entitled, “Neutralizing Antibodies and Antidrug Antibodies in the Ublituximab Phase 3 ULTIMATE I and II Studies in Relapsing Multiple Sclerosis,” on February 24, 2022. The lead author of the third poster Edward Fox of Central Texas Neurology Consultants Round Rock, Tx, will present the poster entitled, “Pharmacodynamics of B-Cell Depletion and Pharmacokinetics of the Novel Anti-CD20 Monoclonal Antibody Ublituximab in Patients With Relapsing Multiple Sclerosis.”
ULTIMATE I & II studies met primary endpoints
ULTIMATE I and II are two separate Phase III randomized, double-blinded, controlled, worldwide, multi-center trials comparing the safety/tolerability and efficacy of ublituximab versus teriflunomide in patients with relapsing forms of MS. An average of 1,094 RMS patients from ten countries were included in the ULTIMATE I and II studies. Both studies meet the primary endpoint with ublituximab treatment showing a statistical reduction in annualized relapse rate.
